BPH

Basic Science Research: Trimodal therapy shows promise in oligometastatic PCaOther basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease.
BPH: Current, forthcoming modalities show efficacyFour-year data on the prostatic urethral lift (UroLift) and data on a new water-jet ablation treatment were among BPH/LUTS highlights from this year’s meeting.
UroLift vs. TURP: New gold standard for BPH?In this video, Neil Baum, MD, compares UroLift with other BPH management strategies and also discusses his experience with the use of nitrous oxide as an effective sedative during in-office urologic procedures.
Prostatic urethral lift (UroLift) placement under topical anesthesiaThis video demonstrates UroLift placement under topical anesthesia in the office setting and also includes comments from several patients who underwent the procedure.
Prostatic urethral lift (UroLift): A minimally invasive approachThis video provides an overview of the prostatic urethral lift (UroLift), highlighting the entire cycle of patient care.
Water ablation’s safety, efficiency in BPH assessedAn image-guided technique for treating LUTS associated with BPH is reproducible and promising, researchers say.
AUA 2016: Experts offer guidance on the meetingTo guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.
Uro Pipeline: FDA grants priority review to advanced bladder Ca agentAlso look for coverage of products in the pipeline for bladder pain syndrome/interstitial cystitis, prostate cancer, and male infertility.
Uro Pipeline: 1st patients treated in phase III study of investigational BPH TxOther pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.
Study: BPH procedure’s benefits sustained at 3 yearsThe prostatic urethral lift (PUL [UroLift, NeoTract, Inc.]) yields successful 3-year durability and superior rate of improvement of BPH symptoms compared to transurethral resection of the prostate, according to separate studies presented at the AUA annual meeting in New Orleans.